Skip to main content
. 2010 Jun 1;59(9):1389–1400. doi: 10.1007/s00262-010-0870-9

Fig. 3.

Fig. 3

Association of MIA expression levels with autoantibody response and clinical outcome. The overexpression of MIA mRNA in cancerous tissues (a) did not coincide with anti-MIA antibody response (b), but tended to be associated with shorter survival (p = 0.076; Kaplan–Meier analysis, (c). In contrast, median survival time was significantly (p < 0.05) longer in the low-expressing group carrying autoantibodies to MIA (MIAlow-Ab Pos, (d)